Annual Meeting of the American Thyroid Association® (ATA) 2025

Booth 301

Location: Scottsdale, Arizona | Westin Kierland
Date: September 10–14, 2025

At a glance

Veracyte is excited to join the American Thyroid Association (ATA) Annual Meeting. Stop by booth #301 to learn how Veracyte is using whole-transcriptome-derived analysis on every sample to provide an actionable Afirma GSC report and create the potential for novel research.

There will be 12 poster presentations, including 7 from Veracyte and 5 independent studies that utilized data from Afirma GSC and Afirma GRID (Genomic Resource for Intelligent Discovery)*, which is a research-use-only resource for analysis of molecular characteristics that may ultimately help improve the understanding of how to manage patients with thyroid nodules and thyroid cancer.

Veracyte’s Medical Director of Endocrinology, Dr. Klopper, will also provide a presentation on Friday, September 12th – more details below.

Featured Presentations & Posters
TitleSessionDateTimePresenterLocation
Veracyte’s Medical Director of Endocrinology Dr. Klopper will describe how Afirma’s whole-exome molecular analysis provides accurate and reproducible results to help in thyroid nodule management and represents a platform for novel research opportunities.
Product Theatre
Friday, September 21
10:15 – 11:15 AM
Dr. Klopper, M.D.
Kierland Grand Ballroom
Product Theatre / Special Sessions
itleSessionDateTimePresenter(s)Location
Development of a Molecular Expression Profile-based Model to Predict High-Risk Histopathologic Features of Differentiated Thyroid Cancer
Poster 237
Friday, September 12
10:15 – 11:15 AM
Justin Bauzon, M.D., Cleveland Clinic
Different Features of Aggressive Cancer Behavior Exhibit Clear Variations in mRNA Expression Patterns: An Analysis of Molecular Signatures in Differentiated Thyroid Cancer
Poster 236
Friday, September 12
10:15 – 11:15 AM
Justin Bauzon, M.D., Cleveland Clinic

mRNA Expression Signatures Enhance Risk Stratification in Indeterminate Thyroid Nodules
Poster 244
Friday, September 12
10:15 – 11:15 AM
Lilah Morris-Wiseman, M.D., FACS, John Hopkins Medicine
The Impact of Nodule Size on Performance of Molecular Testing for Cytologically Indeterminate Thyroid Nodules
Poster 345
Saturday, September 13
10:25 – 11:25 AM
Athanasios Bikas, M.D., Ph.D., Brigham & Women’s
Evaluating Risk of Malignancy in Thyroid Nodules Using Molecular Profiling
Late Breaking Poster 481

Saturday, September 13
10:25 – 11:25 AM
Josie Yalovitser (UVM Larner College of Medicine)
Profiling of Black and White Patients with Indeterminate Thyroid Nodules
Poster 355
Saturday, September 13
10:25 – 11:25 AM
Niranjana Swaminathan, M.D., The University of Alabama at Birmingham
The Genomic Landscape of 250,000+ Thyroid Nodules Undergoing Exome-enriched RNA Sequencing
Poster 338
Saturday, September 13
10:25 – 11:25 AM
Sarah Hamidi, M.D., The University of Texas MD Anderson Cancer Center
Genomic Landscape of Medullary Thyroid Carcinoma (MTC) Identified by the Afirma RNA-Sequencing Classifier: Insights from a Large Real-World Cohort
Poster 336
Saturday, September 13
10:25 – 11:25 AM
Sarah Hamidi, M.D., The University of Texas MD Anderson Cancer Center
The Genomic Landscape of Thyroid Nodules in Patients > 75 Years Old
Poster 344
Saturday, September 13
10:25 – 11:25 AM
Architha Kannan, MBBS, UCSF
The Expression of Cell-Surface Targets as Potential Prognostic and Therapeutic Markers in Thyroid Tumors
Late Breaking Poster 433
Thursday, September 11
3:00 – 4:00 PM
Hannah Nieto, MBBS, Ph.D., University of Birmingham
Preoperative mRNA Thyroid Nodule Expression Signatures to Predict Postoperative Thyroid Histopathology
Late Breaking Poster 442
Friday, September 12
10:15 – 11:15 AM
Genevieve Spagnuolo, M.D., MBS, Tufts University
Single-Cell RNA Sequencing Analysis of Thyroid Nodule Fine Needle Biopsy Aspiration
Late Breaking Poster 470
Saturday, September 13
10:25 – 11:25 AM
Caitlin Bell, M.D., University of Colorado

Keep exploring

Veracyte Diagnostics Platform

A novel diagnostics platform helping unlock deeper cancer insights.

Clinical Studies

Studies demonstrating the impact of our tests across cancer types.

Scientific Publications

Veracyte publications and references showcasing discoveries and advancements.

Press Releases

New data, partner announcements, and financial reports.